Basilea Pharmaceutica (XSWX:BSLN) OCF Margin %: 30.40% (As of Dec. 2025)

What is Basilea Pharmaceutica OCF Margin %?

Basilea Pharmaceutica XSWX:BSLN -0.55% 59 OCF Margin % is 30.40% as of Dec. 2025. GuruFocus rates XSWX:BSLN with a GF Score™ of 59/100 and a GF Value™ of CHF57.66 (Fairly Valued). The stock has 4 warning signs investors should review. Among 950 Biotechnology companies, Basilea Pharmaceutica ranks better than 87.79% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Basilea Pharmaceutica's Cash Flow from Operations for the six months ended in Dec. 2025 was CHF39.0 Mil. Basilea Pharmaceutica's Revenue for the six months ended in Dec. 2025 was CHF128.4 Mil. Therefore, Basilea Pharmaceutica's OCF Margin % for the quarter that ended in Dec. 2025 was 30.40%.

As of today, Basilea Pharmaceutica's current OCF Yield % is 9.17%.

The historical rank and industry rank for Basilea Pharmaceutica's OCF Margin % or its related term are showing as below:

XSWX:BSLN' s OCF Margin % Range Over the Past 10 Years
Min: -113.67 Med: -8.42 Max: 35.66
Current: 26.72

During the past 13 years, the highest OCF Margin % of Basilea Pharmaceutica was 35.66%. The lowest was -113.67%. And the median was -8.42%.

XSWX:BSLN's OCF Margin % is ranked better than
87.79% of 950 companies
in the Biotechnology industry
Industry Median: -65.71 vs XSWX:BSLN: 26.72

Basilea Pharmaceutica OCF Margin % Related Terms

Basilea Pharmaceutica OCF Margin % Historical Data

* Premium members only.

The historical data trend for Basilea Pharmaceutica's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basilea Pharmaceutica OCF Margin % Chart

Basilea Pharmaceutica Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

OCF Margin %

Get a 7-Day Free Trial

-21.62

4.78

9.04

35.66

26.72

Basilea Pharmaceutica Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
OCF Margin %	Get a 7-Day Free Trial															-10.48	23.49	42.68	22.18	30.40

XSWX:BSLN vs VRTX, REGN, ALNY: OCF Margin % Comparison

For the Biotechnology subindustry, Basilea Pharmaceutica's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Basilea Pharmaceutica OCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Basilea Pharmaceutica's OCF Margin % falls into.

Save Embed

59GF Score

Basilea Pharmaceutica Ltd XSWX:BSLN

OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Basilea Pharmaceutica OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Basilea Pharmaceutica's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin	=	Cash Flow from Operations (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	62.09	/	232.38
	=	26.72 %

Basilea Pharmaceutica's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin	=	Cash Flow from Operations (Q: Dec. 2025 )	/	Revenue (Q: Dec. 2025 )
	=	39.034	/	128.42
	=	30.40 %

Frequently Asked Questions Learn more about OCF Margin % →

What does a OCF Margin % of 30.40% mean?

Basilea Pharmaceutica (XSWX:BSLN) has a OCF Margin % of 30.40% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Basilea Pharmaceutica and its competitors. According to the industry distribution chart, Basilea Pharmaceutica ranks #116 out of 950 companies in the Biotechnology industry, placing it in the top 12.2%.

Is Basilea Pharmaceutica's OCF Margin % too high?

Basilea Pharmaceutica's current OCF Margin % is 30.40%. Based on the distribution chart, Basilea Pharmaceutica ranks #116 out of 950 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Basilea Pharmaceutica has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Basilea Pharmaceutica's OCF Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Basilea Pharmaceutica ranks #116 out of 950 companies for OCF Margin %. This places Basilea Pharmaceutica in the top 12% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good OCF Margin % for a Biotechnology company?

A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high OCF Margin % mean?

A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Basilea Pharmaceutica and its competitors. Basilea Pharmaceutica's current OCF Margin % is 30.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Basilea Pharmaceutica stock overvalued right now?

Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Fairly Valued. The stock's GF Value™ is CHF57.66, compared to a current price of CHF54.70 — trading 5.1% below its estimated fair value. The current OCF Margin % is 30.40%. Basilea Pharmaceutica's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is OCF Margin % calculated?

OCF Margin % is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current OCF Margin % is 30.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued. The current stock price of CHF54.70 is trading 5.1% below its estimated GF Value™ of CHF57.66. GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.

Key valuation signals for XSWX:BSLN:

OCF Margin %: 30.40%
GF Value™: CHF57.66 vs. price of CHF54.70 (5.1% below fair value)
GF Score™: 59/100 with 4 warning signs

No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Basilea Pharmaceutica Business Description

Industry Healthcare Biotechnology

Comparable Companies XSWX:NWRN XSWX:SANN XSWX:BIOV XSWX:MOLN XSWX:XLS XSWX:MMTX XSWX:ADXN XSWX:IDIA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA XKRX:068270 RPRX

Other Exchanges BPMUF:USA BSLNz:UK 0QNA:UK PK5:Germany

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123

Website https://www.basilea.com

Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.

59GF Score

Get the complete analysis for XSWX:BSLN

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF54.70

Price

CHF57.66

GF Value

View XSWX:BSLN Analysis

See OCF Margin % data for all stocks →